Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 8/20 | 0.51 |
| ▸ | BCHE | P06276 | 6/20 | 0.51 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.51 |
| ▸ | GRIN2A | Q12879 | 4/20 | 0.51 |
| ▸ | ELANE | P08246 | 2/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6471555 | 0.84 | ACHE (0.41) | ACHEBCHEGRIN1GRIN2AELANE | |
| SCHEMBL6470489 | 0.74 | ACHE (0.39) | ACHEBCHEGRIN1GRIN2A | |
| SCHEMBL5391180 | 0.73 | ACHE (0.54) | ACHEBCHEGRIN1GRIN2AELANE | |
| SCHEMBL5824154 | 0.72 | ALDH1A1 (0.49) | ACHEBCHEGAAALOX15 | |
| SCHEMBL8781938 | 0.71 | ACHE (0.47) | ACHEBCHEGRIN1GRIN2AELANE | |
| SCHEMBL2722636 | 0.70 | CXCR5 (0.42) | GAA | |
| SCHEMBL2702396 | 0.70 | CXCR5 (0.42) | GAA | |
| SCHEMBL8787861 | 0.70 | CD44 (0.43) | GRIN1GRIN2AGAA | |
| SCHEMBL5824150 | 0.69 | ALDH1A1 (0.49) | ACHEBCHEGAAALOX15 | |
| SCHEMBL6471553 | 0.68 | PSMB5 (0.40) | ACHEBCHEGRIN1GRIN2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | TAISHO PHARMACEUTICAL CO., LTD. | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | HCRTR2, MCHR1, MCHR2 | ACHE 197/4885BCHE 119/4885GRIN1 257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.